Zusheng Xu

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

L. Qiu, Yuqin Song, Bo Jiang, 2021, Journal of Hematology & Oncology.

Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

D. Zhong, L. Miao, Yifan Zhang, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.

Z. Wang, Xiaohong Xu, Y. Shu, 2021 .

A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.

Y. Shu, Tianshu Liu, H. Bao, 2021 .

The prognostic value of miRNA-18a-5p in clear cell renal cell carcinoma and its function via the miRNA-18a-5p/HIF1A/PVT1 pathway

Yuanlei Chen, Gong-hui Li, Li-qun Xia, 2020, Journal of Cancer.

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Jun Yu Li, Dengju Li, Zengjun Li, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Z. Cai, Zhiming Li, H. Cen, 2021, Blood.